SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by Arizona State Retirement System

Arizona State Retirement System increased its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 20.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,491 shares of the company’s stock after acquiring an additional 2,618 shares during the period. Arizona State Retirement System’s holdings in SpringWorks Therapeutics were worth $584,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. SG Americas Securities LLC grew its position in SpringWorks Therapeutics by 8.3% in the 1st quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock valued at $230,000 after buying an additional 358 shares in the last quarter. First Horizon Advisors Inc. grew its position in SpringWorks Therapeutics by 47.9% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock valued at $45,000 after buying an additional 383 shares in the last quarter. American International Group Inc. grew its position in SpringWorks Therapeutics by 1.2% in the 1st quarter. American International Group Inc. now owns 33,751 shares of the company’s stock valued at $1,661,000 after buying an additional 394 shares in the last quarter. Teacher Retirement System of Texas grew its position in SpringWorks Therapeutics by 5.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,268 shares of the company’s stock valued at $375,000 after buying an additional 498 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its position in SpringWorks Therapeutics by 20.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock valued at $220,000 after buying an additional 754 shares in the last quarter.

Wall Street Analyst Weigh In

SWTX has been the subject of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $77.00 target price (up previously from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. JPMorgan Chase & Co. raised their price objective on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, HC Wainwright restated a “buy” rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics has a consensus rating of “Buy” and a consensus target price of $68.50.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX opened at $35.56 on Tuesday. The company has a 50 day simple moving average of $38.20 and a 200-day simple moving average of $41.68. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of -6.92 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.58. The company had revenue of $59.73 million during the quarter, compared to analysts’ expectations of $34.42 million. SpringWorks Therapeutics’s revenue for the quarter was up 59732900.0% compared to the same quarter last year. During the same period last year, the company earned ($1.25) earnings per share. On average, analysts predict that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.